| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6269 |
Provisional Schedule
| Committee meeting | 11 November 2025 |
| Expected publication | 29 January 2026 |
Project Team
| Project lead | Leena Issa |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
Stakeholders
| Companies sponsors | Eli Lilly |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Blood Cancer UK |
| CLL Support | |
| Leukaemia UK | |
| Lymphoma Action | |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Abbvie (venetoclax) – confidentiality agreement signed, participating |
| AstraZeneca (acalabrutinib) – confidentiality agreement signed, participating | |
| BeOne Medicines UK (zanubrutinib) – confidentiality agreement signed, participating | |
| Celltrion Healthcare (rituximab) – confidentiality agreement not signed, not participating | |
| Gilead Sciences (idelalisib) – confidentiality agreement not signed, not participating | |
| Janssen-Cilag (ibrutinib) – confidentiality agreement signed, participating | |
| Pfizer (rituximab) – confidentiality agreement not signed, not participating | |
| Roche (rituximab) – confidentiality agreement not signed, not participating | |
| Sandoz (rituximab) – confidentiality agreement not signed, not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health – Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| NHS Wales Joint Commissioning Committee | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 April 2025 | Invitation to participate |
| 21 February 2025 - 07 March 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 08 August 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2025. |
| 04 April 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 28 February 2024 - 27 March 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6269 |
| 28 February 2024 | In progress. Scoping commenced. |
| 20 March 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual